Evolution of the Average Target: Black Diamond Therapeutics, Inc.

Evolution of the Target Price: Black Diamond Therapeutics, Inc.

Changes in Analyst Recommendations: Black Diamond Therapeutics, Inc.

69d526792d6d41a6fd52cce98537.m74Mt2PLGMAZi046dGEYjCvWeT3NReM-gGoJtEdUvnU.1PZP3wKNeo1p-yRsMFd_206yKlG6fKZX7ws-0QY2ih7PjD3kWp1I9UPkdg~dd7398e25f6713e6a65fb8df2979a310
03-17 Wedbush Lifts Price Target on Black Diamond Therapeutics to $14 From $13, Keeps Outperform Rating MT
25-08-07 Black Diamond Therapeutics Q2 net loss narrows as costs drop RE
25-03-07 Wedbush Adjusts Black Diamond Therapeutics Price Target to $11 From $16, Maintains Outperform Rating MT
24-07-31 Raymond James Initiates Black Diamond Therapeutics at Outperform MT
24-05-16 HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating MT
24-04-08 Wedbush Adjusts Price Target on Black Diamond Therapeutics to $16 From $10 After Market Confirmation for Drug, Maintains Outperform Rating MT
23-07-14 Piper Sandler Initiates Black Diamond Therapeutics With Overweight Rating, $11 Price Target MT
23-06-30 Stifel Upgrades Black Diamond Therapeutics to Buy From Hold, Adjusts Price Target to $10 From $2 MT
23-06-28 HC Wainwright Upgrades Black Diamond Therapeutics to Buy From Neutral, Price Target is $11 MT
23-06-27 Wedbush Upgrades Black Diamond Therapeutics to Outperform From Neutral, Adjusts Price Target to $10 From $3 MT
22-05-12 Wedbush Lowers Price Target for Black Diamond Therapeutics to $3 From $4, Maintains Neutral Rating MT
22-04-01 Berenberg Bank Adjusts Black Diamond Therapeutics Price Target to $16 From $34, Maintains Buy Rating MT
22-03-29 Wedbush Downgrades Black Diamond Therapeutics to Neutral From Outperform, Citing BDTX-1535 Timeline, Likely BDTX-189 Discontinuation, 'Tough' Financing Environment; PT to $4 From $22 MT
22-03-22 HC Wainwright Downgrades Black Diamond Therapeutics to Neutral From Buy MT
22-03-18 Stifel Adjusts Price Target on Black Diamond Therapeutics to $4 From $10, Reiterates Hold Rating MT
21-09-30 BLACK DIAMOND THERAPEUTICS : Stifel Starts Black Diamond Therapeutics at Hold With $10 Price Target MT
21-08-17 BLACK DIAMOND THERAPEUTICS : Wedbush Lowers PT for Black Diamond Therapeutics to $22 From $48 Following BDTX-189 Data, Reiterates Outperform Rating MT
21-08-17 BLACK DIAMOND THERAPEUTICS : Berenberg Bank Adjusts Black Diamond Therapeutics PT to $34 From $58, Maintains Buy Rating MT
21-05-21 BLACK DIAMOND THERAPEUTICS : Wedbush Removes Outperform-Rated Black Diamond Therapeutics From Best Ideas List; Price Target is $48 MT
21-03-29 BLACK DIAMOND THERAPEUTICS : Wedbush Adds Outperform-Rated Black Diamond Therapeutics to Best Ideas List; Price Target is $48 MT
21-03-26 BLACK DIAMOND THERAPEUTICS : Wedbush Adjusts Price Target on Black Diamond Therapeutics to $48 From $45, Keeps Outperform Rating MT
21-01-07 BLACK DIAMOND THERAPEUTICS : Wedbush Starts Black Diamond Therapeutics at Outperform With $45 Price Target MT
20-11-24 BLACK DIAMOND THERAPEUTICS : Berenberg Starts Black Diamond Therapeutics at Buy With $58 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+493.8%
+11.3%
+42.1%
+36.27%
+105.79%
+51.99%
+42.17%
-5.61%
+31.71%
-23.54%
Average +78.60%
Weighted average by Cap. +33.42%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.660USD
Average target price
9.857USD
Spread / Average Target
+493.80%
High Price Target
14.00USD
Spread / Highest target
+743.37%
Low Price Target
7.000USD
Spread / Lowest Target
+321.69%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Wedbush
HC Wainwright
Piper Sandler
Stifel Nicolaus
Berenberg Bank
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.660USD
Average target price
9.857USD
Spread / Average Target
+493.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock
  4. Consensus Black Diamond Therapeutics, Inc.
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!